Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 616 AL 630

Potential therapeutic agents against Alzheimer's disease from natural sources

Park SY.

Arch Pharm Res. 2010 Oct;33(10):1589-609. doi: 10.1007/s12272-010-1010-y. Epub 2010 Oct 30.

Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative

Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Nov;67(11):1370-8. doi: 10.1001/archneurol.2010.284.

A meta-analysis of mood stabilizers for Alzheimer's disease

Xiao H, Su Y, Cao X, Sun S, Liang Z.

J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):652-8. doi: 10.1007/s11596-010-0559-5. Epub 2010 Nov 10.

Amyloid-independent mechanisms in Alzheimer's disease pathogenesis

Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH.

J Neurosci. 2010 Nov 10;30(45):14946-54. doi: 10.1523/JNEUROSCI.4305-10.2010.

Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice

Li S, He H, Cui W, Gu B, Li J, Qi Z, Zhou G, Liang CM, Feng XY.

Anat Rec (Hoboken). 2010 Dec;293(12):2136-43. doi: 10.1002/ar.21209.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80.

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial

Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR.

J Clin Psychopharmacol. 2010 Dec;30(6):683-7. doi: 10.1097/jcp.0b013e3181fa05bb.

Small vascular and Alzheimer disease-related pathologic determinants of dementia in the oldest-old

Sinka L, Kövari E, Gold G, Hof PR, Herrmann FR, Bouras C, Giannakopoulos P.

J Neuropathol Exp Neurol. 2010 Dec;69(12):1247-55. doi: 10.1097/NEN.0b013e3181ffc3b9.

Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease

Lannfelt L, Pettersson FE, Nilsson LN.

Nutr Rev. 2010 Dec;68 Suppl 2:S128-34. doi: 10.1111/j.1753-4887.2010.00347.x.

Reduced Alzheimer's disease ß-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin

Meckler X, Roseman J, Das P, Cheng H, Pei S, Keat M, Kassarjian B, Golde TE, Parent AT, Thinakaran G.

J Neurosci. 2010 Dec 1;30(48):16160-9. doi: 10.1523/JNEUROSCI.4436-10.2010.

No answer to Alzheimer's disease?

Chu Y, Heistad DD.

Circ Res. 2010 Dec 10;107(12):1400-2. doi: 10.1161/CIRCRESAHA.110.234450. Epub 2010 Dec 2.

Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment

Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K.

Molecules. 2010 Dec 2;15(12):8804-12. doi: 10.3390/molecules15128804.

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J.

Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808.

Insulin-resistant brain state (IRBS) changes membrane composition of fatty acids in temporal and entorhinal brain cortices of rats: relevance to sporadic Alzheimer's disease?

Plaschke K, Müller D, Hoyer S.

J Neural Transm (Vienna). 2010 Dec;117(12):1419-22. doi: 10.1007/s00702-010-0523-3. Epub 2010 Dec 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias